The clinical problem

“Peptides” has become a buzzword, attached to claims that range from legitimate to entirely unfounded. At the same time, the regulatory status of many peptide compounds is genuinely in flux. The result is widespread confusion about what peptide therapy actually is, what the evidence supports, and what is safe and lawful.

The UroLongevity approach

Peptides are short chains of amino acids, and they are not a single thing — they range from well-characterized, approved therapies to compounds whose evidence is early or whose regulatory status is unsettled. The practice’s posture is to engage with this area honestly: explain what the evidence supports, acknowledge what remains uncertain, and be clear about the regulatory reality. Anything specific to your situation — whether peptide therapy is appropriate for you at all, and if so what that involves — is determined within the clinical relationship, supervised and monitored. It is not something this website can or should prescribe.

◆ Dr. Shusterman’s take

Peptides are where longevity medicine is noisiest and least disciplined. My job on this page is narrow and deliberate: explain the category honestly, and route every specific question into a consultation where it can be answered safely, lawfully, and for you in particular.

What’s involved

At a high level, evaluation and intervention may include:

  • An honest assessment of whether peptide therapy is appropriate for you, in the context of your full picture
  • Evidence-grounded discussion of what specific compounds are and are not supported to do
  • A clear account of regulatory status — including where it is unsettled or changing
  • Clinical supervision and monitoring for any therapy undertaken
  • A firm boundary: no dosing, no sourcing guidance, and no encouragement of gray-market acquisition — here or in consultation
On dosing Specific dosing and protocols are individualized to your clinical picture and decided in consultation. They are not published here, because one-size guidance is not good medicine.

Honest expectations

Some peptide therapies have a reasonable evidence base for specific uses. Many do not, or are still early. A responsible practice will tell you honestly which is which, will not promise what cannot be supported, and will not help anyone obtain compounds outside a legitimate, supervised clinical framework. If that posture is more cautious than what you have read elsewhere, that is the point.

Important — please read carefully Peptide therapy is an area of active regulatory change. Many peptide compounds exist in a shifting regulatory landscape, including changes affecting compounding under section 503A. This page explains, at a general level, what peptide therapy is and the evidence-based posture the practice takes. It deliberately does not provide dosing, does not provide sourcing or acquisition guidance, and should not be read as encouragement to obtain any compound outside a legitimate clinical relationship. Self-prescribing peptides, or obtaining them from gray-market sources, carries real risks of contamination, mislabeling, and harm. Any appropriate use of peptide therapy is determined, supervised, and monitored within a clinical relationship. Specifics belong in a consultation, not on a public page.